An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression

BACKGROUND: Many patients with Parkinson’s disease (PD) experience depression. OBJECTIVE: Evaluate pimavanserin treatment for depression in patients with PD. METHODS: Pimavanserin was administered as monotherapy or adjunctive therapy to a selective serotonin reuptake inhibitor or serotonin/noradrena...

Descripción completa

Detalles Bibliográficos
Autores principales: DeKarske, Daryl, Alva, Gustavo, Aldred, Jason L., Coate, Bruce, Cantillon, Marc, Jacobi, Lori, Nunez, Rene, Norton, James C., Abler, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683094/
https://www.ncbi.nlm.nih.gov/pubmed/32804101
http://dx.doi.org/10.3233/JPD-202058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683094/
https://www.ncbi.nlm.nih.gov/pubmed/32804101
http://dx.doi.org/10.3233/JPD-202058

Ejemplares similares